ライフサイエンスコーパス: patient receiving

1 The single patient receiving 12 weeks of ledipasvir-sofosbuvir who

2 n contrast, PFS was inferior in ABVD-treated patients receiving 20 Gy instead of 30 Gy IF-RT (10-year

3 and hematologic toxicity in late-stage mCRPC patients receiving (223)RaCl2 Further prospective studie

4 Dose-limiting CLS occurred in 2 of 4 patients receiving 30 microg/kg of moxetumomab pasudotox

5 Observational cohort of LTBI patients receiving 3HP through 16 US programs was used t

6 Six of 14 patients receiving 50 microg/kg of moxetumomab pasudotox

7 ssess the time to a first AF diagnosis among patients receiving a CIED for purposes of AF detection.

8 raphic, clinical, and tumor characteristics, patients receiving a complete vs incomplete radiation do

9 ylation inhibition was seen by day 8 in most patients receiving a daily dose of 80 mg or higher.

10 Of patients receiving a filter (11405 in the PTOS, 71029 in

11 In this retrospective analysis all patients receiving a first HCT between January 2004 and

12 The study included all patients receiving a first index diagnosis of nonorganic

13 A total of 91199 patients receiving a first index diagnosis of nonorganic

14 er outcome than do the other pediatric T-ALL patients receiving a high-risk adapted therapy.

15 nationwide, prospective cohort study of 8026 patients receiving a kidney, heart, lung, or liver trans

16 fixed paraffin-embedded tissue samples of 22 patients receiving a lung retransplantation due to BOS o

17 veloped a transient immune response, despite patients receiving a median of 10 doses.

18 Almost 1 in 5 older patients receiving a secondary prevention ICD survives a

19 y hormonal therapies were allowed, except in patients receiving a standard, first-generation antiandr

20 In chronic HF patients receiving ACE inhibition, plasma Ang II was sup

21 cant shift toward TCH over time, with 88% of patients receiving ACTH in 2005 compared with 15% by 201

22 Data from 1,077 patients receiving ACTH or TCH were analyzed, and the pr

23 es evidence of enhanced clinical effects for patients receiving active ABMT.

24 itinib plus methotrexate, and 36 (9%) of 386 patients receiving adalimumab plus methotrexate disconti

25 erse events were reported more frequently in patients receiving adalimumab than in those receiving pl

26 cohort study of CM (N = 221), we found that patients receiving adjunctive corticosteroids had a sign

27 djusted risk of new persistent opioid use in patients receiving adjuvant chemotherapy was 15% to 21%,

28 Consistent with this observation, patients receiving adjuvant gemcitabine (n = 107) with e

29 isolated from pre-therapy plasma of the AML patients receiving adoptive NK-92 cell therapy block ant

30 ents led to treatment discontinuation for 13 patients receiving ADS-5102 (20.6%) vs 4 patients receiv

31 However, patients receiving ADT eventually develop incurable cast

32 Clinical management of patients receiving AIT and efficacy in randomised contro

33 e data on the progression of AR and/or AA in patients receiving AIT.

34 e of acute cellular rejection was seen in HS patients receiving alemtuzumab (P = 0.001), there was a

35 ed with a somewhat elevated bleeding risk in patients receiving allogeneic stem cell transplants (SCT

36 ompared with participants receiving placebo, patients receiving an antidepressant reported significan

37 Patients receiving an AVF had a higher median annual cos

38 Compared with patients receiving an isolated LVAD, patients requiring

39 12 months was 0.024 (CI, 0.021 to 0.027) for patients receiving angiography within 2 months of their

40 Ang-(1-7) was elevated, whereas acute HF and patients receiving angiotensin receptor blocker had high

41 es in HS pediatric patients as nonsensitized patients receiving anti-IL-2R induction.

42 center retrospective analysis of 31 lymphoma patients receiving anti-PD-1 mAbs for relapse post-allo-

43 All patients receiving anti-PD-1 monoclonal antibodies were

44 igmentation may be a good response marker in patients receiving anti-PD1/anti-PD-L1 therapy for LC.

45 red nineteen studies (68%) were performed in patients receiving antibiotic therapy for a range of 1-7

46 l leaflet thrombosis was less frequent among patients receiving anticoagulants (eight [4%] of 224) th

47 Most patients receiving antiplatelet therapy (3613 of 4527 [8

48 Viral load (VL) monitoring for patients receiving antiretroviral therapy (ART) is recom

49 l load point-of-care (PoC) assays to monitor patients receiving antiretroviral therapy.

50 compared 30 day all-cause mortality between patients receiving appropriate (including an active drug

51 e cases (61%), including 63 studies (59%) in patients receiving appropriate antibiotic therapy starte

52 th infection in most patients, including all patients receiving appropriate antimicrobial therapy, wi

53 eumoniae (375 [86%] of 437; 291 [85%] of 343 patients receiving appropriate therapy vs 84 [89%] of 94

54 infection) or inappropriate therapy, and for patients receiving appropriate therapy, between those re

55 ontrolled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation

56 s revealed that mortality was much higher in patients receiving ART from the DDFs than sentinel hospi

57 In HIV-infected patients receiving ART, chronic co-infection with HBV an

58 Efficacy and safety were assessed in all patients receiving at least 1 dose of treatment.

59 as available) and the safety analysis in all patients receiving at least one dose of fedratinib.

60 For both phases 1 and 2, all patients receiving at least one dose of study drug were

61 In the intention-to-treat population, patients receiving atezolizumab had fewer grade 3-4 trea

62 (range, 1 to 43 months), the ORR was 38% for patients receiving azacitidine, 49% for azacitidine plus

63 To evaluate outcomes in patients receiving balanced fluids for resuscitation in

64 percutaneous coronary intervention to SVG in patients receiving bare-metal stents (BMS), first-genera

65 One hundred and sixteen eyes of fifty-eight patients receiving bilateral implantation of the study i

66 ough previous studies have demonstrated that patients receiving bilateral internal mammary artery (BI

67 ereas this frequency was 15.1% (n=196) among patients receiving BIMA (P=0.004).

68 e of repeat coronary revascularization among patients receiving BIMA and SIMA.

69 freedom from repeat revascularization among patients receiving BIMA than among patients receiving SI

70 urgeries with BIMA were identified, and 1297 patients receiving BIMA were propensity-matched to 1297

71 rence in 30-day cumulative mortality between patients receiving blood stored for 30 to 42 days and th

72 nt visits and hospitalizations compared with patients receiving bortezomib (without IMiDs), but 1-yea

73 Compared with controls, patients receiving both components of optimal GDMT (n =

74 public health initiatives, the proportion of patients receiving bystander CPR increased at home (from

75 HCV-infected patients receiving cancer treatment at our institution b

76 Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in

77 reactivation occurred in 23% of HCV-infected patients receiving cancer treatment, and most had an unr

78 al Record Interactive Search to identify all patients receiving care from CRTs in two National Health

79 Stroke patients receiving care in minority hospitals had lower

80 In addition to stroke or death in patients receiving carotid endarterectomy, a harm of scr

81 uly 27, 2010, to September 19, 2013, in 4631 patients receiving CCTA as their initial test, with a me

82 nce claims data for 678220 privately insured patients receiving chemotherapy before and after the Oct

83 Patients receiving chemotherapy could cross over to rece

84 ata from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower r

85 In very high-risk patients receiving combination haploidentical single-uni

86 y patients, SSIs occurred in 58/6,607 (0.9%) patients receiving combination prophylaxis versus 146/10

87 study we compared the incidence of AKI among patients receiving combination therapy with VPT to a mat

88 We reviewed data for all patients receiving commercially approved devices from 20

89 Patients receiving commercially funded TAVR in the Unite

90 They were paradoxically more frequent for patients receiving compliant initial care.

91 gested survival benefit with lestaurtinib in patients receiving concomitant azole antifungal prophyla

92 Thirty-four (34%) of 101 patients receiving concomitant ITP medication discontinu

93 Full clinical remission occurred in 11 (20%) patients receiving corticosteroid monotherapy and three

94 of biopsy-proven acute rejection was seen in patients receiving corticosteroids tapered over 10 days

95 e examined by ELISA and PCR sequencing in UC patients receiving corticosteroids.

96 ith CRT use and examined overall survival of patients receiving CRT versus RT.

97 FDA identified 29 unique reports of HBV-R in patients receiving DAAs from 22 November 2013 to 15 Octo

98 health and perceived social support) of HCV patients receiving DAAs therapy prior, during and at the

99 roke, bleeding, and myocardial infarction in patients receiving dabigatran versus warfarin in practic

100 t of Multivessel disease) trial, we compared patients receiving DAPT (aspirin plus thienopyridine) an

101 primary composite outcomes were similar for patients receiving DAPT versus aspirin monotherapy respe

102 o evaluate clinical response and survival in patients receiving de novo versus upgrade CRT defibrilla

103 nfluences the risk of calciphylaxis in adult patients receiving dialysis and examined the effects of

104 experimental hyperparathyroidism models and patients receiving dialysis and studied the function of

105 lity-based, controlled trial involving >9000 patients receiving dialysis from 134 dialysis facilities

106 During neoadjuvant treatment, compared with patients receiving docetaxel, carboplatin, and trastuzum

107 l studies have described DRMs that emerge in patients receiving dolutegravir.

108 ever, 2 of 10, 4 of 10, 4 of 10, and 7 of 10 patients receiving doses of 4, 6, 7.4, and 9.3 GBq, resp

109 s Honokiol as a promising therapy for cancer patients receiving Dox treatment.

110 100 mg twice daily, with a minimum of three patients receiving each dose.

111 onal normalized ratio values were similar in patients receiving EBR/GZR and placebo; among patients w

112 Patients receiving EC-D reported significantly more stom

113 Adult patients receiving either a patient-centred pressure ulc

114 e analysis of acute-on-chronic liver failure patients receiving either standard medical treatment or

115 in lesions have only rarely been reported in patients receiving epidermal growth factor receptor inhi

116 les predict length of hospital stay (LOS) in patients receiving ERAS protocols and conventional care.

117 Patients receiving escitalopram had more frequent sleepi

118 Compared to adalimumab, patients receiving etanercept were more likely to discon

119 In trials A and B, respectively, patients receiving etelcalcetide had more muscle spasms

120 ysis was to compare the incidence of WHAE in patients receiving everolimus (EVR) or mycophenolate sod

121 the incidence and severity of stomatitis in patients receiving everolimus and exemestane and could b

122 and could be a new standard of oral care for patients receiving everolimus and exemestane therapy.

123 Patients receiving EVR showed a higher risk of developin

124 Patients receiving first-line or subsequent dasatinib or

125 se risk index-matched acute myeloid leukemia patients receiving fludarabine-melphalan without TBI.

126 The patients receiving fluids within 30 minutes had lowest m

127 ts of any grade occurred in 244 (43%) of 571 patients receiving FOLFOX alone and 274 (54%) of 507 pat

128 erse event was neutropenia (137 [24%] of 571 patients receiving FOLFOX alone vs 186 (37%) of 507 pati

129 s receiving FOLFOX alone vs 186 (37%) of 507 patients receiving FOLFOX plus SIRT).

130 receiving FOLFOX alone and 274 (54%) of 507 patients receiving FOLFOX plus SIRT.

131 pr3 simultaneously may be beneficial for the patients receiving FTY720 treatment.

132 At baseline, patients receiving GA were younger and had a shorter del

133 We identified 12364 and 1071 patients receiving gastric bypass and gastric banding, r

134 weeks), 35% (8 weeks), and 48% (12 weeks) of patients receiving GED-0301 were in remission (CD activi

135 low-up time was 36 months (IQR 30-46) in the patients receiving gemcitabine, busulfan, and melphalan

136 Patients receiving glimepiride, canagliflozin 100 mg, or

137 omplete remission obtained in 73% (11/15) of patients receiving >/=1 x 10(6) CD22-CAR T cells per kg

138 patients and 45.7% of birch pollen-allergic patients receiving guideline-concordant therapy were reg

139 Consecutive patients receiving guideline-recommended treatment for H

140 Among patients receiving HCT, 27 (40%) had graft-versus-host d

141 assess whether HBV-R is a safety concern in patients receiving HCV DAAs.

142 The optimal BP target for patients receiving hemodialysis is unknown.

143 g acid-base balance is less well defined for patients receiving hemodialysis than for those receiving

144 Our study included 20 patients receiving hemodialysis with calciphylaxis (case

145 lled treatment trials were conducted in 1023 patients receiving hemodialysis with moderate to severe

146 Among patients receiving hemodialysis with moderate to severe

147 Among patients receiving hemodialysis with moderate to severe

148 ebo and oral cinacalcet vs IV placebo in 683 patients receiving hemodialysis with serum parathyroid h

149 modialysis with calciphylaxis (cases) and 20 patients receiving hemodialysis without calciphylaxis (c

150 k for major adverse cardiovascular events in patients receiving hemodialysis, a full-scale trial is n

151 ciate with an increased risk of mortality in patients receiving hemodialysis, but high values are a m

152 parathyroid hormone (PTH) concentrations in patients receiving hemodialysis.

153 Control is suboptimal in the majority of patients receiving hemodialysis.

154 Hematologic toxicity was more severe for patients receiving higher absorbed radiation doses, indi

155 32 (63% [95% CI 48-76]) of 51 patients receiving higher dose luspatercept concentratio

156 Five-year OS for patients receiving HMA, LEN, and MISC was 36.5%, 41.7%,

157 In both scenarios, a proportion of patients receiving HPN were eventually eligible for an i

158 E/mL on CRBSI occurrence.Forty-one high-risk patients receiving HPS followed in a tertiary HPS unit w

159 dy assessed morbidity and mortality of older patients receiving ICDs for secondary prevention in cont

160 wo hundred twenty two well-controlled asthma patients receiving ICS or ICS/LABA were assessed for phy

161 vaccinatum and inform assessment of risks in patients receiving IL-1 blocking Abs for treatment of ch

162 Safety was generally similar between patients receiving immediate treatment and those receivi

163 P=0.02), but the rate did not differ between patients receiving immunosuppressive combination and con

164 ed to improve the measurement of response in patients receiving immunotherapy.

165 Most patients receiving intravenous 5-fluorouracil develop si

166 Advantage individuals, was used to identify patients receiving intravitreal anti-VEGF injections bas

167 . 36.7%, (p < 0.001)), due to polymetastases patients receiving involved-sites radiotherapy with low

168 Overall, patients receiving IVC filters had lower risk for subseq

169 alyses were based on overall 97 patients, 45 patients receiving IVF plus LD versus 42 with IVF only.

170 Patients receiving l-methylfolate exhibited convergent c

171 nt adverse events were reported in 328 (74%) patients receiving lacosamide and 332 (75%) receiving ca

172 Among 4,710 patients receiving large-volume fluid resuscitation, hyp

173 -103 are each reasonable isotope options for patients receiving LDR brachytherapy; no recommendation

174 edian creatinine change did not differ among patients receiving LDV/SOF and tenofovir disoproxil fuma

175 A cohort of heart failure (HF) patients receiving left ventricular assist devices (LVAD

176 is was performed to compare outcomes between patients receiving LMWH and UH.

177 in the disease progression of HIV-1-infected patients receiving long-term antiretroviral therapy sugg

178 In contrast, the majority of patients receiving long-term combination antiretroviral

179 a source of worsened functional status among patients receiving long-term opioid therapy.

180 nto improvements in bone and renal health in patients receiving long-term treatment remains to be see

181 d the diagnostic performance of cFFR between patients receiving low or iso-osmolality contrast (n=574

182 023), 46.3% (370 mug), and 38.6% (70 mug) of patients receiving LPP vs 25.6% of patients receiving pl

183 Patients receiving LT for IBDI were more likely women (5

184 d doses revealed a clear distinction between patients receiving </=5 mg (n = 64) and >5 mg (n = 53) d

185 routine cancer screening among asymptomatic patients receiving maintenance dialysis on the basis of

186 ter observational study over 3 months of all patients receiving mechanical ventilation in 36 intensiv

187 Among comatose patients receiving mechanical ventilation, those without

188 ated hypercapnia and hypercapnic acidosis in patients receiving mechanical ventilation.

189 RATIONALE: The weaning process concerns all patients receiving mechanical ventilation.

190 x score <150) at week 8 occurred in 49.2% of patients receiving MEDI2070 (n = 59) compared with 26.7%

191 alence of hepatitis B vaccination among U.S. patients receiving medical care for HIV infection ("HIV

192 A total of 313 fluid foci in 50 eyes of 25 patients receiving MEK inhibitors for treatment of their

193 Corticosteroid-free remission with the patient receiving mesalazine treatment only at 12 weeks

194 applied to create comparable groups between patients receiving MIG or OG, using year of surgery and

195 heral neuropathy occurred in 11 (11%) of 104 patients receiving momelotinib (one of which was grade 3

196 mide depleted regulatory T cells in 24 of 27 patients receiving MVA-5T4, independently prolonging PFS

197 ty (HR, 0.77; 95% CI, .66-.90) compared with patients receiving nafcillin or oxacillin, after control

198 dualised annual prediction of risk of PML in patients receiving natalizumab for multiple sclerosis, s

199 e performed, demonstrates that breast cancer patients receiving neoadjuvant chemotherapy have no incr

200 studying acute respiratory distress syndrome patients receiving neuromuscular blockade.

201 tility of the PaO2/FiO2 ratio in classifying patients receiving NIV, and the impact of NIV on outcome

202 en through month 12 (M12), the proportion of patients receiving no IAIs, and the role of macular lase

203 h a reduced treatment frequency, with 30% of patients receiving no IAIs.

204 Patients receiving noninvasive ventilation were more lik

205 al of 27.8 months, significantly superior to patients receiving nonsurgical therapy (10.6 months) and

206 or this source of calories in critically ill patients receiving nutrition on CVVH may result in overf

207 In-hospital mortality was higher among patients receiving off-label TAVR than those receiving o

208 Overall, patients receiving omalizumab had a similar reaction pro

209 Eight of the 9 patients receiving omalizumab reacted during desensitiza

210 on-inotrope-dependent advanced heart failure patients receiving optimal medical management, the SHFM

211 y dose of oral corticosteroids among the 165 patients receiving oral corticosteroids, in prednisone e

212 suppression was maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 pati

213 rogeneous resistance mechanisms developed in patients receiving osimertinib.

214 ted and did not differ significantly between patients receiving PaCE and those receiving CE.

215 ciated with a reduction in the proportion of patients receiving packed red blood cell (PRBC) using a

216 DAPT with high scores was effective only in patients receiving paclitaxel-eluting stents (RD, -7.55

217 the dialysis effluent for membrane change in patients receiving PD.

218 eports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab.

219 her proportion of nonmechanically ventilated patients receiving physical therapy/occupational therapy

220 ysis of three phase III IPF clinical trials, patients receiving pirfenidone had a lower risk of nonel

221 13 patients receiving ADS-5102 (20.6%) vs 4 patients receiving placebo (6.9%).

222 0 mug) of patients receiving LPP vs 25.6% of patients receiving placebo (modified per-protocol set).

223 Over the treatment period, patients receiving placebo or bosutinib had similar annu

224 We retrospectively reviewed 119 patients receiving Pneumocystis pneumonia prophylaxis pr

225 n of a PBM program was associated with fewer patients receiving PRBC transfusion using a liberal trig

226 as well as an increase in the proportion of patients receiving PRBC using a restrictive trigger hemo

227 However, a higher proportion (10%) of patients receiving prednisolone developed an infection a

228 The 2 x 2 factorial design led to 547 patients receiving prednisolone; 546 were treated with p

229 Subset analysis of those patients receiving primary surgery as treatment showed n

230 d all acute NHS hospitals in England and all patients receiving primary THA.

231 Patients receiving prophylaxis had longer duration of ne

232 d time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify

233 as the incidence of grade 2 or higher HFS in patients receiving pyridoxine.

234 Most patients receiving radiation also received sequential/co

235 the most common clinical adverse effect for patients receiving radiotherapy as part of the standard

236 However, overall survival in patients receiving radiotherapy remained very good, with

237 Patients receiving ramipril had improvement in microvasc

238 e the timing of palliative care referrals in patients receiving rapid response team services, and pat

239 Of patients receiving renal replacement therapy, neither po

240 For patients receiving RRT, target attainment rates were >80

241 r, some disease-related symptoms improved in patients receiving ruxolitinib relative to BAT.

242 The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacater

243 Patients receiving second-generation DES for the treatme

244 fter nocardiosis and describe the outcome of patients receiving short-course antibiotics (</=120 days

245 ion among patients receiving BIMA than among patients receiving SIMA (hazard ratio [HR], 0.78 [95% CI

246 Among the matched cohort, 19.4% (n=252) of patients receiving SIMA underwent repeat revascularizati

247 ceiving BIMA were propensity-matched to 1297 patients receiving SIMA.

248 luded duration of antibiotics, proportion of patients receiving single doses or brief courses of anti

249 At week 52, of all patients receiving sirukumab including those reassigned

250 The proportion of patients receiving specific treatment in other African c

251 Methods Patients receiving stable opioid therapy and experiencin

252 At 5 years, 85.9% (95% CI 84.3-87.3) of patients receiving standard epirubicin and 87.1% (85.6-8

253 The high mortality rates of cancer patients receiving standard treatments emphasize the cru

254 matched cohort resulted in a sample of 1,475 patients receiving statin matched 1:1 with control patie

255 For patients receiving statin therapy unchanged from baselin

256 Outcome analyses by dose quartiles of these patients receiving sunitinib or sorafenib were also perf

257 Patients receiving surgical therapy (n = 25) had a media

258 Despite improved visual outcomes, uveitis patients receiving systemic immunosuppressive therapy ma

259 after detection of intestinal metastasis in patients receiving systemic treatment was 22 months.

260 y enhance therapeutic responses for melanoma patients receiving targeted or immune-based therapies.

261 Patients receiving TCH were significantly more likely to

262 Patients receiving tDCS had higher rates of skin redness

263 a-glutamyl transferase were observed in some patients receiving telotristat ethyl.

264 udies have described the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside

265 clinical fractures is significantly lower in patients receiving teriparatide than in those receiving

266 A total of 507 eyes of 289 patients receiving the Artisan Myopia or Artisan Toric (

267 ng a Gaussian repeated measures model in all patients receiving the first ECT treatment.

268 The primary outcome was the proportion of patients receiving the preferred beta-lactam therapy.

269 Fewer injections were required in patients receiving the T&E (8.7) versus monthly (11.1) r

270 permanent pacemaker was implanted in 4.5% of patients receiving the THV (4.9% for patients at risk).

271 scores declined in treated Nine of 32 (28%) patients receiving therapy and only one of 15 (7%) patie

272 sed risk of lymphoma has been reported among patients receiving thiopurines for inflammatory bowel di

273 red the outcome of 13 acute myeloid leukemia patients receiving this conditioning regimen with age an

274 16 US metropolitan regions, resulted in more patients receiving timely reperfusion.

275 Treatment was well tolerated; fewer patients receiving tiw versus qw were positive for neutr

276 Two (1%) of the 384 patients receiving tofacitinib monotherapy died.

277 In total, 23 (6%) of 384 patients receiving tofacitinib monotherapy, 26 (7%) of 3

278 ving tofacitinib monotherapy, 26 (7%) of 376 patients receiving tofacitinib plus methotrexate, and 36

279 atin, and trastuzumab plus pertuzumab, fewer patients receiving trastuzumab emtansine plus pertuzumab

280 ned better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-ther

281 mon dose-limiting side effect experienced by patients receiving treatment for cancer.

282 to have broad applicability to CRVO and HRVO patients receiving treatment for macular edema.

283 overall survival in multiple cohorts of AML patients receiving treatment with the cytidine nucleosid

284 Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adher

285 Patients receiving TTFC maintained better treatment adhe

286 Patients receiving ultrasound-guided subclavian or inter

287 5% confidence interval = 1.24-2.83), whereas patients receiving ustekinumab were more likely to persi

288 of treatment, compared with 106 (59%) of 179 patients receiving vancomycin (difference 11% [95% CI 1.

289 acillin-tazobactam (VPT) compared to similar patients receiving vancomycin + cefepime (VC) are lackin

290 ing rates of acute kidney injury (AKI) among patients receiving vancomycin + piperacillin-tazobactam

291 Recent evidence suggests that among patients receiving vancomycin, receipt of concomitant pi

292 -hour mean arterial pressure in septic shock patients receiving vasopressin who were on chronic renin

293 are the hemodynamic response in septic shock patients receiving vasopressin who were on chronic renin

294 Patients receiving VC were matched to patients receiving

295 ranted, these findings could be relevant for patients receiving VEGF antagonists.

296 and nausea were reported more frequently by patients receiving voxilaprevir.

297 Studying adult ICU patients receiving VPI at submaximal dosages, we analyze

298 Patients receiving VC were matched to patients receiving VPT based on severity of illness, int

299 ospital from 2005 to 2010, the proportion of patients receiving VTE prophylaxis or with an indication

300 De-escalation was possible for patients receiving weekly adalimumab and azathioprine or